BioSpace News Archive

STRATA Skin Sciences, Inc., a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced an expanded direct distribution agreement with Wuhan Miracle Laser Systems, Inc., that provides for both recurring revenues from placements and direct capital from sales in China.

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number 10,940,181 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that three late-breaking abstracts have been accepted for presentation at the 103rd Annual Meeting and Expo of the Endocrine Society (ENDO 2021) to be held virtually March 20-23.

4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-310 for the treatment of Fabry disease.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that it will present today new data from its Alzheimer’s trials with vafidemstat, ETHERAL and REIMAGINE-AD, at the 15th International Conference

Tri-anim Health Services, a specialty distributor of respiratory, anesthesia and critical care supplies, announced that it has entered into an exclusive relationship to represent and distribute the ReddyPort™ portfolio of products.

The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics, Inc. (NASDAQ: PTCT) have entered into a new collaboration focused on regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders with the goal of developing new treatments.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced that the company initiated a second pre-clinical study in animals for potential treatment of liver fibrosis

Melior’s therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies

- Marketing Application in Canada (New Drug Submission) Planned for First Half of 2021 - Amylyx Also Plans to Pursue Early Access Options in Canada